ChemoCentryx is a leading late stage biotech company producing oral drugs for treating auto-immune diseases, inflammatory disorders and cancer. It is a pioneer in research into the chemokine network (network of signal substances) that plays a crucial role in regulating the immune system. Crohn’s disease, rheumatoid arthritis and multiple sclerosis are some of the diseases which ChemoCentryx has programmes to combat. In 2006 it concluded a cooperation agreement with GlaxoSmithKline for its Traficet-EN treatment of irritable bowel syndrome. ChemoCentryx went public on the Nasdaq in February 2012.
- Activity: Research into the chemokine network
- Website: www.chemocentryx.com
- Location: United States
- Entry: 2004
- Platform: Health & Care